Australia's most trusted
source of pharma news
Friday, 18 April 2025
Posted 10 April 2025 AM
Omico has announced its first partnership with a national private cancer care provider, making its genomic profiling available across Icon Cancer Centre's extensive national network of centres.
The partnership focuses on Omico's PrOSPeCT (Precision Oncology Screening Program Enabling Clinical Trials), which will give 23,000 patients with advanced, incurable or poor prognosis cancers free comprehensive genomic profiling to identify potential matches with clinical trials.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.